دورية أكاديمية
أعرض في EDS

Advancing Vaccinology Capacity: Education and Efforts in Vaccine Development and Manufacturing across Africa.

التفاصيل البيبلوغرافية
العنوان: Advancing Vaccinology Capacity: Education and Efforts in Vaccine Development and Manufacturing across Africa.
المؤلفون: Sinumvayo JP; Department of Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda.; East African Community, Regional Center of Excellence for Vaccines, Immunization and Health Supply Chain Management (EAC RCE-VIHSCM), Kigali P.O. Box 3286, Rwanda.; Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and Pharmacy, University of Rwanda, Rwanda, Kigali P.O. Box 3286, Rwanda., Munezero PC; Department of Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda.; Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and Pharmacy, University of Rwanda, Rwanda, Kigali P.O. Box 3286, Rwanda., Tope AT; Department of Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda.; Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and Pharmacy, University of Rwanda, Rwanda, Kigali P.O. Box 3286, Rwanda., Adeyemo RO; Department of Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda.; Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and Pharmacy, University of Rwanda, Rwanda, Kigali P.O. Box 3286, Rwanda., Bale MI; Department of Microbiology and Parasitology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda.; Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and Pharmacy, University of Rwanda, Rwanda, Kigali P.O. Box 3286, Rwanda., Nyandwi JB; East African Community, Regional Center of Excellence for Vaccines, Immunization and Health Supply Chain Management (EAC RCE-VIHSCM), Kigali P.O. Box 3286, Rwanda.; Department of Pharmacology and Toxicology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda., Haakuria VM; East African Community, Regional Center of Excellence for Vaccines, Immunization and Health Supply Chain Management (EAC RCE-VIHSCM), Kigali P.O. Box 3286, Rwanda., Mutesa L; Department of Biochemistry, Molecular Biology and Genetics, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda.; Center for Human Genetics, College of Medicine and Health Sciences, University of Rwanda, Kigali P.O. Box 4285, Rwanda., Adedeji AA; Future of Medicine, Science, Technology and Innovation Research Group, School of Medicine and Pharmacy, University of Rwanda, Rwanda, Kigali P.O. Box 3286, Rwanda.; Department of Pharmacology and Toxicology, School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda, Huye P.O. Box 117, Rwanda.
المصدر: Vaccines [Vaccines (Basel)] 2024 Jul 03; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 03.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI AG
مستخلص: Africa, home to the world's second-largest population of approximately 1.3 billion, grapples with significant challenges in meeting its medical needs, particularly in accessing quality healthcare services and products. The continent faces a continuous onslaught of emerging infectious diseases, exacerbating the strain on its already fragile public health infrastructure. The COVID-19 crisis highlighted the urgency to build local vaccine production capacity and strengthen the health infrastructure in general. The risks associated with a heavy reliance on imported vaccines were exposed during the COVID-19 pandemic, necessitating the need to nurture and strengthen the local manufacturing of vaccines and therapeutic biologics. Various initiatives addressing training, manufacturing, and regulatory affairs are underway, and these require increasing dedicated and purposeful financial investment. Building vaccine manufacturing capacity requires substantial investment in training and infrastructure. This manuscript examines the current state of education in vaccinology and related sciences in Africa. It also provides an overview of the continent's efforts to address educational needs in vaccine development and manufacturing. Additionally, it evaluates the initiatives aimed at strengthening vaccine education and literacy, highlighting successful approaches and ongoing challenges. By assessing the progress made and identifying the remaining obstacles, this review offers insights into how Africa can enhance its vaccine manufacturing capacity to respond to vaccine-preventable disease challenges.
References: N Engl J Med. 2021 Feb 11;384(6):541-549. (PMID: 33567193)
Pan Afr Med J. 2013;14:44. (PMID: 23560127)
Emerg Infect Dis. 2008 Aug;14(8):1327. (PMID: 18680676)
APMIS. 2021 Jul;129(7):352-371. (PMID: 33244837)
Infect Dis (Lond). 2022 May;54(5):315-324. (PMID: 35007473)
Ann Glob Health. 2024 Jan 29;90(1):7. (PMID: 38312714)
Infection. 2023 Jun;51(3):697-704. (PMID: 36307576)
Vaccine. 2020 Feb 29;38 Suppl 1:A118-A126. (PMID: 31879125)
Lancet Infect Dis. 2019 Aug;19(8):872-879. (PMID: 31285143)
Lancet Infect Dis. 2022 Dec;22(12):1728-1736. (PMID: 36087586)
Curr Top Microbiol Immunol. 2014;379:117-44. (PMID: 24827501)
Hum Vaccin Immunother. 2022 Dec 31;18(1):2020529. (PMID: 35086416)
Virol Sin. 2022 Aug;37(4):477-482. (PMID: 35820590)
Science. 2020 Aug 14;369(6505):846-849. (PMID: 32576668)
Vaccine. 2020 Jul 14;38(33):5364-5371. (PMID: 32563607)
Afr J Lab Med. 2018 Dec 06;7(2):781. (PMID: 30568900)
Vaccine X. 2023 May 27;14:100320. (PMID: 37293248)
Front Immunol. 2023 Apr 24;14:1172691. (PMID: 37168860)
Lancet HIV. 2020 Oct;7(10):e688-e698. (PMID: 33010242)
North Clin Istanb. 2015 Apr 24;2(1):81-86. (PMID: 28058346)
Vaccine. 2019 May 16;37(22):2871-2881. (PMID: 30898392)
Nature. 2021 Mar;591(7851):520-522. (PMID: 33737753)
Emerg Microbes Infect. 2022 Dec;11(1):1657-1663. (PMID: 35678141)
J Infect Dis. 2018 Oct 15;218(suppl_3):S137-S140. (PMID: 30184102)
Biosci Trends. 2022 Sep 17;16(4):312-316. (PMID: 35908851)
JAMA Netw Open. 2022 Feb 01;5(2):e220527. (PMID: 35226079)
Lancet Infect Dis. 2022 Mar;22(3):377-389. (PMID: 34801112)
Hum Vaccin Immunother. 2016 Sep;12(9):2334-40. (PMID: 27159397)
Rev Esp Quimioter. 2023 Feb;36(1):30-44. (PMID: 36503203)
Prev Vet Med. 2018 Jul 1;155:1-10. (PMID: 29786519)
Comput Math Methods Med. 2022 Jan 13;2022:3163854. (PMID: 35069779)
NPJ Vaccines. 2019 Feb 18;4:11. (PMID: 30792905)
Health Sci Rep. 2022 Jan 06;5(1):e468. (PMID: 35024458)
Infect Dis Poverty. 2021 Mar 6;10(1):24. (PMID: 33676581)
Vaccines (Basel). 2023 Mar 01;11(3):. (PMID: 36992153)
Signal Transduct Target Ther. 2023 Sep 20;8(1):365. (PMID: 37726283)
Nature. 2022 Feb;602(7896):184. (PMID: 35140392)
Acta Trop. 2022 Aug;232:106498. (PMID: 35513072)
Acta Trop. 2023 Feb;238:106743. (PMID: 36343664)
Front Public Health. 2019 Mar 20;7:56. (PMID: 30949465)
Front Immunol. 2021 Aug 18;12:703986. (PMID: 34484200)
Vaccine. 2017 Jul 24;35(33):4064-4071. (PMID: 28647170)
Interface Focus. 2022 Feb 11;12(2):20210072. (PMID: 35261731)
Lancet. 2017 Nov 25;390(10110):2397-2409. (PMID: 28673422)
Viruses. 2022 May 05;14(5):. (PMID: 35632709)
Nat Rev Dis Primers. 2020 Feb 20;6(1):13. (PMID: 32080199)
Lancet. 1986 Jul 19;2(8499):124-7. (PMID: 2873397)
Pathog Glob Health. 2020 May;114(3):136-144. (PMID: 32308158)
Pan Afr Med J. 2021 Mar 29;38:313. (PMID: 34285736)
Clin Exp Vaccine Res. 2022 Jan;11(1):82-88. (PMID: 35223668)
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):186-91. (PMID: 26884499)
BMC Health Serv Res. 2021 May 5;21(1):426. (PMID: 33952253)
Nat Rev Microbiol. 2023 Feb;21(2):87-96. (PMID: 36097163)
Nat Commun. 2021 Feb 10;12(1):916. (PMID: 33568638)
N Engl J Med. 2022 Dec 29;387(26):2411-2424. (PMID: 36516078)
BMJ Glob Health. 2019 Sep 20;4(5):e001363. (PMID: 31637022)
Vaccine. 2017 Dec 4;35(48 Pt B):6759-6765. (PMID: 29037578)
Vaccine. 2011 Aug 11;29(35):5821-3. (PMID: 21718743)
Nat Med. 2021 Mar;27(3):447-453. (PMID: 33531710)
Vaccine. 2022 Sep 16;40(39):5683-5690. (PMID: 36030127)
Clin Trials. 2022 Dec;19(6):647-654. (PMID: 35866633)
PLoS One. 2016 Jun 03;11(6):e0156674. (PMID: 27258124)
Lancet Infect Dis. 2024 Jun;24(6):602-610. (PMID: 38340736)
Virol J. 2019 Dec 30;16(1):165. (PMID: 31888676)
Lancet. 2018 Feb 10;391(10120):552-562. (PMID: 29217376)
Cell. 2020 Oct 15;183(2):296-300. (PMID: 33064983)
J Vector Borne Dis. 2020 Apr-Jun;57(2):105-113. (PMID: 34290154)
Vaccine. 2023 Jan 9;41(2):397-406. (PMID: 36460535)
Vaccine. 2020 Jun 19;38(30):4664-4670. (PMID: 32475535)
Front Vet Sci. 2022 Mar 09;8:558973. (PMID: 35356415)
Pragmat Obs Res. 2021 May 27;12:37-47. (PMID: 34079423)
Vaccines (Basel). 2022 Oct 25;10(11):. (PMID: 36366303)
BMC Infect Dis. 2021 Oct 23;21(1):1089. (PMID: 34688249)
Pathogens. 2021 Oct 14;10(10):. (PMID: 34684274)
Nat Hum Behav. 2021 May;5(5):557-565. (PMID: 33785897)
Lancet Infect Dis. 2021 Sep;21(9):1282-1292. (PMID: 34019802)
Lancet. 2022 Apr 16;399(10334):1513-1536. (PMID: 35279232)
فهرسة مساهمة: Keywords: African countries; education; vaccine manufacturing; vaccinology
تواريخ الأحداث: Date Created: 20240727 Latest Revision: 20240729
رمز التحديث: 20240729
مُعرف محوري في PubMed: PMC11281707
DOI: 10.3390/vaccines12070741
PMID: 39066380
قاعدة البيانات: MEDLINE
الوصف
تدمد:2076-393X
DOI:10.3390/vaccines12070741